Transparency too little, too late? Why and how Health Canada should make clinical data and regulatory decision-making open to scrutiny in the face of COVID-19.

Edmonds, Sterling; MacGregor, Andrea; Doll, Agnieszka; Vural, Ipek Eren; Graham, Janice; Fierlbeck, Katherine; Lexchin, Joel; Doshi, Peter; Herder, Matthew

Edmonds, Sterling; MacGregor, Andrea; Doll, Agnieszka; Vural, Ipek Eren; Graham, Janice; Fierlbeck, Katherine; Lexchin, Joel; Doshi, Peter; Herder, Matthew.

Afiliação

Edmonds S; Schulich School of Law, Dalhousie University.
MacGregor A; Schulich School of Law, Dalhousie University.
Doll A; Schulich School of Law, Dalhousie University.
Vural IE; Schulich School of Law, Dalhousie University.
Graham J; Department of Pediatrics (Infectious Diseases), Dalhousie University.
Fierlbeck K; Department of Political Science, Dalhousie University.
Lexchin J; School of Health Policy and Management, York University.
Doshi P; Department of Pharmaceutical Health Services Research, University of Maryland School of Pharmacy.
Herder M; Schulich School of Law, Dalhousie University.

J Law Biosci ; 7(1): lsaa083, 2020.

Article em En | MEDLINE | ID: mdl-33537149

Palavras-chave

COVID-19; pandemic; pharmaceutical regulation; transparency; vaccines and drugs

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: J Law Biosci Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google